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Table S-1: Full antiparasitic screening panel and enzymatic activity on TbrPDEB1 and hPDE4 of the final compounds.
Comp. T.brucei T.cruzi L.infantum P. falciparum MRC5 PMM TbrPDEB1 hPDE4
1 6.35 ± 0.08 4.42 ± 0.05 4.19 ± 0.01 4.96 ± 0.23 4.35 ± 0.18 4.19 ± 0.01 7.36 ± 0.26 10.27 ± 0.17
2 6.45 ± 0.12 5.07 ± 0.03 5.20 ± 0.80 6.02 ± 0.48 4.93 ± 0.35 4.80 ± 0.50 7.18 ± 0.28 9.99 ± 0.18
3 5.77 ± 0.02 4.52 ± 0.01 4.48 ± 0.01 5.03 ± 0.18 4.75 ± 0.17 4.34 ± 0.21 6.98 ± 0.15 9.06 ± 0.22
4 6.06 ± 0.25 5.57 ± 0.10 5.36 ± 0.20 5.34 ± 0.23 5.13 ± 0.04 5.10 ± 0.01 6.19 ± 0.10 8.61 ± 0.05
5 5.75 ± 0.06 5.03 ± 0.01 4.77 ± 0.38 5.13 ± 0.31 4.19 ± 0.01 4.19 ± 0.01 6.47 ± 0.05 9.17 ± 0.08
6 5.77 ± 0.16 5.07 ± 0.02 4.69 ± 0.01 4.87 ± 0.11 4.19 ± 0.01 4.49 ± 0.01 6.19 ± 0.03 9.23 ± 0.24
7 6.58 ± 0.03 5.39 ± 0.51 4.69 ± 0.01 5.26 ± 0.23 5.52 ± 0.4 4.49 ± 0.01 6.19 ± 0.13 9.65 ± 0.21
8 5.44 ± 0.44 4.61 ± 0.59 4.85 ± 0.07 4.93 ± 0.15 5.41 ± 0.15 4.49 ± 0.01 6.59 ± 0.16 9.29 ± 0.06
9 5.73 ± 0.07 4.86 ± 0.36 4.63 ± 0.09 4.44 ± 0.12 4.76 ± 0.02 4.49 ± 0.01 6.96 ± 0.21 9.50 ± 0.21
10 5.64 ± 0.05 5.08 ± 0.03 4.37 ± 0.01 5.51 ± 0.27 4.19 ± 0.01 4.19 ± 0.01 6.16 ± 0.06 9.20 ± 0.26
11 6.44 ± 0.13 5.21 ± 0.22 4.91 ± 0.25 5.69 ± 0.48 4.22 ± 0.06 4.49 ± 0.01 7.37 ± 0.03 6.45 ± 0.11
12 6.09 ± 0.16 5.09 ± 0.04 5.18 ± 0.08 5.73 ± 0.06 5.11 ± 0.01 5.1 ± 0.01 7.61 ± 0.08 9.81 ± 0.05
14 5.73 ± 0.05 4.19 ± 0.00 4.19 ± 0.00 4.47 ± 0.00 4.19 ± 0.00 4.19 ± 0.00 7.68 ± 0.14 10.21 ± 0.08
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15 5.74 ± 0.02 4.19 ± 0.01 4.19 ± 0.01 5.53 ± 0.04 4.19 ± 0.01 4.19 ± 0.01 7.12 ± 0.10 9.77 ± 0.04
16 4.19 ± 0.01 4.19 ± 0.01 4.19 ± 0.01 4.24 ± 0.01 4.19 ± 0.01 4.19 ± 0.01 7.01 ± 0.21 9.50 ± 0.14
17 6.32 ± 0.05 4.91 ± 0.12 4.49 ± 0.01 5.37 ± 0.32 4.50 ± 0.38 4.49 ± 0.01 7.51 ± 0.06 9.81 ± 0.03
24 5.7 ± 0.01 5.16 ± 0.2 5.40 ± 0.14 5.41 ± 0.36 4.19 ± 0.01 4.49 ± 0.01 6.08 ± 0.09 7.52 ± 0.16
25 5.68 ± 0.03 5.63 ± 0.03 5.45 ± 0.50 4.94 ± 0.29 4.19 ± 0.01 4.80 ± 0.43 <5.03 nd
26 5.72 ± 0.04 5.16 ± 0.07 5.64 ± 0.03 5.40 ± 0.24 4.19 ± 0.01 4.80 ± 0.43 <5.08 nd
27 4.88 ± 0.43 5.10 ± 0.77 4.93 ± 0.34 4.93 ± 0.36 4.42 ± 0.32 4.49 ± 0.01 <5.25 nd
28 4.19 ± 0.01 4.37 ± 0.25 4.49 ± 0.01 4.61 ± 0.05 4.53 ± 0.01 4.19 ± 0.01 7.11± 0.06 9.92 ± 0.23
29 4.99 ± 0.01 4.81 ± 0.46 4.99 ± 0.04 4.75 ± 0.06 4.19 ± 0.01 4.49 ± 0.01 <5.02 nd
30 4.49 ± 0.00 4.81 ± 0.48 4.79 ± 0.32 4.64 ± 0.08 4.39 ± 0.02 4.49 ± 0.01 <4.78 nd
31 4.48 ± 0.01 5.1 ± 0.01 4.79 ± 0.43 4.19 ± 0.01 4.19 ± 0.01 <5.34 nd
32 4.32 ± 0.18 4.70 ± 0.29 4.43 ± 0.09 4.51 ± 0.04 4.19 ± 0.01 <5,01 nd
35 6.00 ± 0.42 4.37 ± 0.02 4.34 ± 0.21 5.57 ± 0.05 4.19 ± 0.01 4.34 ± 0.21 6.39 ± 0.01 9.52 ± 0.14
36 5.12 ± 0.06 4.34 ± 0.2 4.24 ± 0.07 5.39 ± 0.39 4.19 ± 0.01 4.19 ± 0.01 6.11 ± 0.04 9.32 ± 0.08
37 5.30 ± 0.07 5.11 ± 0.01 5.09 ± 0.18 5.14 ± 0.14 4.61 ± 0.33 4.80 ± 0.43 6.05 ± 0.11 7.20 ± 0.15
38 5.17 ± 0.01 5.68 ± 0.02 5.09 ± 0.01 5.42 ± 0.04 4.19 ± 0.01 4.80 ± 0.43 <5.67 nd
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39 5.48 ± 0.36 5.19 ± 0.04 5.08 ± 0.02 5.41 ± 0.07 4.19 ± 0.01 4.80 ± 0.43 <5.78 nd
41 4.19 ± 0.01 4.19 ± 0.01 4.19 ± 0.01 4.19 ± 0.01 4.19 ± 0.01 4.19 ± 0.01 <4.50 nd
42 4.49 ± 0.01 4.19 ± 0.01 4.27 ± 0.11 4.27 ± 0.11 4.19 ± 0.01 4.19 ± 0.01 <4.50 nd
43 4.19 ± 0.01 4.19 ± 0.01 4.19 ± 0.11 4.27 ± 0.01 4.19 ± 0.01 4.19 ± 0.01 <4.74 nd
44 6.06 ± 0.23 5.09 ± 0.02 5.03 ± 0.09 5.21 ± 0.56 4.37 ± 0.20 4.65 ± 0.30 7.03 ± 0.20 9.18 ± 0.16
45 5.71 ± 0.16 4.8 ± 0.36 4.52 ± 0.06 5.21 ± 0.51 4.90 ± 0.24 4.19 ± 0.01 <5.01 nd
46 4.34 ± 0.21 4.37 ± 0.24 4.56 ± 0.19 4.37 ± 0.24 4.19 ± 0.01 <4.65 nd
47 5.12 ± 0.01 5.09 ± 0.01 5.09 ± 0.01 5.13 ± 0.29 4.19 ± 0.01 4.19 ± 0.01 <5.16 nd
48 5.71 ± 0.01 4.39 ± 0.12 4.33 ± 0.19 5.11 ± 0.41 4.25 ± 0.07 4.19 ± 0.01 7.07 ± 0.18 9.79 ± 0.28
49 5.19 ± 0.03 5.00 ± 0.05 4.77 ± 0.29 5.31 ± 0.26 4.19 ± 0.01 4.42 ± 0.11 <5.80 nd
51 5.11 ± 0.11 4.9 ± 0.01 4.59 ± 0.14 5.17 ± 0.72 4.95 ± 0.06 4.49 ± 0.01 <5.43 nd
56 4.49 ± 0.01 4.96 ± 0.05 4.58 ± 0.08 5.54 ± 0.03 4.60 ± 0.02 4.49 ± 0.01 <5.69 nd
59 5.11 ± 0.03 4.77 ± 0.01 4.41 ± 0.07 5.73 ± 0.05 4.19 ± 0.01 4.29 ± 0.17 6.56 ± 0.01 8.93 ± 0.07
60 4.82 ± 0.39 4.19 ± 0.01 4.29 ± 0.17 6.13 ± 0.23 4.19 ± 0.01 4.29 ± 0.17 6.54 ± 0.03 9.25 ± 0.04
61 5.74 ± 0.01 4.19 ± 0.01 4.19 ± 0.01 4.58 ± 0.32 4.19 ± 0.01 4.19 ± 0.01 6.99 ± 0.22 9.41 ± 0.09
62 5.94 ± 0.31 4.31 ± 0.16 4.38 ± 0.12 5.05 ± 0.36 4.19 ± 0.01 4.19 ± 0.01 7.04 ± 0.18 9.07 ± 0.17
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The antiprotozoal assays were performed at the Laboratory of Microbiology, Parasitology 
and Hygiene (LMPH), Antwerp University, adopting the set of standard protocols.1 
Inhibitory concentrations 50% (IC50 values) were determined from five 4-fold dilutions 
starting from a maximum concentration of 64 μM.
Cytotoxicity assay
Human lung fibroblast MRC-5SV2 cells (Sigma Aldrich) were cultured in Earl’s MEM, 
supplemented with 5% heat-inactivated fetal bovine serum (FBSi), 20 mM L-glutamine 
and 16.5 mM sodium bicarbonate. Assays were performed in 96-well microtiter plates, 
each well containing 1 × 104 cells. After incubation for 72 h in a humidified atmosphere 
(37°C, 5% CO2) and addition of resazurin, cell viability was assessed fluorimetrically (λex 
550 nm, λem 590 nm). The results are expressed as % reduction in cell growth/ viability 
compared to untreated control wells and IC50 values were determined. Tamoxifen was 
included as reference drug.
Trypanosoma brucei brucei assay
The suramin-sensitive strain Trypanosoma b. brucei Squib 427 was maintained in HMI-
9- medium, supplemented with 10% FBSi. Assays were performed in 96-well microtiter 
plates, each well containing 10 μL of the dilution of compound together with 190 μL of 
the parasite suspension (7 × 104 parasites/mL). After incubation in a humidified 
atmosphere (37°C, 5% CO2) for 72 h, resazurin was added for another 24 h and parasite 
growth was assessed fluorimetrically (λex = 550 nm, λem = 590 nm). The results are 
1 Cos P, Vlietinck AJ, Berghe DV, Maes L. Anti-infective potential of natural products: how to develop a 
stronger in vitro 'proof-of-concept'. J Ethnopharmacol. 2006;106(3):290-302
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expressed as % reduction in parasite growth/viability compared to control wells. Suramin 
was included as reference drug. 
Trypanosoma cruzi assay
The nifurtimox-sensitive Trypanosoma cruzi, Tulahuen CL2, β-galactosidase strain was 
maintained in MRC-5SV2 cells in MEM medium, supplemented with 200 mM L-
glutamine, 16.5 mM sodium bicarbonate and 5% FBSi. Assays were performed in 96-
well microtiter plates, each well containing 10 μL of the compound dilution and 190 μL 
of MRC-5SV2 cell/parasite inoculum (2 × 104 cells/mL and 2 × 105 parasites/mL). After 
incubation for 168 h, parasite growth was compared to untreated-infected controls. 
Parasite burdens were assessed after adding 50 μL/well of a stock solution containing 
15.2 mg CPRG (chlorophenolredβ-D-galactopyranoside) and 250 μL Nonidet in 100 ml 
PBS. The change in color was measured spectrophotometrically at 540 nm after 4 h at 37 
°C. The results were expressed as % reduction in parasite burdens compared to control 
wells. Nifurtimox was included as reference drug.
Leishmania infantum assay
Leishmania infantum MHOM/MA (BE)/67 was maintained in the golden hamster and 
spleen-derived amastigotes were collected for infection. Primary peritoneal mouse 
macrophages (PMM) were used as host cells and collected 48 h after peritoneal 
stimulation with a 2% potato starch suspension. Assays were performed in 96-well 
microtiter plates, each well containing 10 μL of the dilution of compound together with 
190 μL of macrophage/parasite inoculum (3 × 105 cells and 3 × 106 parasites/well in 
RPMI-1640 + 5% FBSi). After incubation for 120 h, total parasite burdens were 
microscopically assessed after Giemsa staining. The results are expressed as % reduction 




The chloroquine-resistant strain of P. falciparum (Pf-K1) was maintained in RPMI-1640 
supplemented with 0.37 mM hypoxanthine, 25 mM HEPES buffer, 25 mM sodium 
bicarbonate and 10% human 0+ serum together with 2–4% washed human 0+ erythrocytes. 
All cultures and assays were conducted under a humidified atmosphere (37°C, 4% CO2, 
3% O2 and 93% N2). Assays were performed in 96-well microtiter plates, each well 
containing 10 μL of the compound dilutions together with 190 μL of parasite inoculum 
(1% parasitaemia, 2% hematocrit). After incubation for 72 h, the plates were frozen and 
stored at −20°C. Upon thawing, 20 μL of each well was transferred into another plate 
together with 100 μL Malstat® reagent and 20 μL of a 1/1 mixture of PES (phenazine 
methosulfate, 2 mg/mL) and NBT (Nitro Blue Tetrazolium Grade III, 0.1 mg/ml). The 
plates were kept in the dark for 2 h and change in color was measured 
spectrophotometrically at 655 nm. The results are expressed as % reduction in 
parasitaemia compared to control wells. Chloroquine was included as reference drug.
Enzymatic assay protocol on TBrPDEB1 and hPDE4.




The assay is performed in Corning non-binding, low volume 384 well plates (article 
number: CLS3824-50EA) and Stimulation Buffer (S.B.) (50mM Hepes, 100mM NaCl, 
10mM MgCl, 0.5mM EDTA, 0.05mg/ml BSA, pH 7.5)
Generation of dose-response curves and pKi calculation:
Three independently generated dose-response curves are generated for each compound.
S10
Results
Data are analysed using GraphPad Prism and the Ki is calculated (µM) using the 
Cheng-Prusoff equation:




𝐩𝐊𝐢 = ―𝟏 × 𝐋𝐨𝐠𝟏𝟎 (𝐊𝐢 ÷ 𝟏𝟎𝟎𝟎𝟎𝟎𝟎)
Microsomal stability
Components of the assay
Male mouse and human liver microsomes were purchased from commercial sources 
(Corning) and stored at -80°C. NADPH generating system solutions A and B and UGT 
reaction mix solutions A and B were purchased from a commercial source (Corning) and 
kept at -20°C. 
Microsomal stability assay
The microsomal stability assay was carried out based on the BD Biosciences Guidelines 
for Use (TF000017 Rev1.0) (Addendum 2) with minor adaptations. The metabolic 
stability of the compounds was studied through the CYP450 superfamily (Phase-I 
metabolism) by fortification with reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) and through uridine glucuronosyl-transferase (UGT) enzymes (Phase-II 
metabolism) by fortification with uridine diphosphate glucuronic acid (UDPGA). For the 
CYP450 and other NADPH dependent enzymes, both compounds were incubated at 5 
μM together with 0.5 mg/mL liver microsomes in potassium phosphate buffer in a 
reaction started by the addition of 1 mM NADPH and stopped at the above listed sampling 
times. At these time points, 20 μl was withdrawn from the reaction mixture and 80 μl cold 
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acetonitrile (ACN), containing the internal standard tolbutamide, was added to inactivate 
the enzymes and precipitate the protein. The mixture was vortexed for 30 sec and 
centrifuged at 4 °C for 5 min at 15,000 rpm. The supernatant was stored at -80 °C until 
analysis. For the UGT enzymes, both compounds were incubated at 5 μM together with 
0.5 mg/mL liver microsomes in a reaction started by the addition of 2 mM UDPGA 
cofactor.
Bioanalytical method 
The corresponding loss of parent compound was determined using liquid chromatography 
(UPLC) (Waters AquityTM) coupled with tandem quadrupole mass spectrometry (MS²) 
(Waters XevoTM), equipped with an electrospray ionization (ESI) interface and operated 
in multiple reaction monitoring (MRM) mode. The optimal MS parameters and control 
of the chromatographic separation conditions were tuned in a preceding experiment
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Results
Raw results of mouse and human microsomal stability are shown in Tables S-2 – S-4. Each value is the mean of at least two experiments. 
Table S-2. Mouse microsomal stability.
Microsomal stability
% remaining parent compound
Microsomes Phase I/II Time (min) 1 2 11 14 17 26 28 29 31 diclofenac
0 100 100 100 100 100 100 100 100 100 100
15 31 ± 3.6 5.7 ± 3.1 8.3 ± 2.4 69 ± 0.4 10 ± 0.6 60 ± 6.1 50 ± 11.6 7.3 ± 1.9 7.2 ± 2.0 87 ± 2.3
30 6.7 ± 1.5 1.7 ± 1.1 3.1 ± 0.6 43 ± 4.5 3.7 ± 3.5 35 ± 2.2 23 ± 8.2 1.1 ± 0.3 2.1 ± 1.2 70 ± 5.5
CYP450-
NADPH
60 1.9 ± 1.3 1.3 ± 0.1 2.3 ± 1.8 21 ± 2.1 1 ± 0.2 17 ± 3.3 7.2 ± 2.6 0.6 ± 0.2 3 ± 2.1 48 ± 1.2
0 100 100 100 100 100 100 100 100 100 100
15 102 ± 3.3 106 ± 2.9 87 ± 1.8 96 ± 1.5 99 ± 6.2 100 ± 15.5 113 ± 20.8 103 ± 11.8 107 ± 5.3 41 ± 1




60 99 ± 9.7 97 ± 24.3 54 ± 6.3 101 ± 1.2 91 ± 2.1 104 ± 2.3 106 ± 41.1 95 ± 11.1 122 ± 4.8 34 ± 2
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Table S-3. Mouse microsomal stability.
Microsomal stability
% remaining parent compound
Microsomes Phase I/II Time (min) 35 38 44 45 47 48 49 61 diclofenac
0 100 100 100 100 100 100 100 100 100
15 8.8 ± 3.3 58 ± 9.1 19 ± 2.3 6.6 ± 1.7 8.5 ± 1.1 49 ± 3.2 19 ± 11.2 0.4 ± 0.01 87 ± 2.3
30 1.8 ± 1.3 44.9 ± 20.2 6.9 ± 0.5 0.4 ± 0.0 3 ± 1.2 20 ± 2.1 5 ± 3.2 0.6 ± 0.9 70 ± 5.5
CYP450-
NADPH
60 0.4 ± 0.3 16.3 ± 9.5 4.4 ± 0.2 3.5 ± 4.7 2.6 ± 0.7 3.4 ± 0.4 1 ± 0.8 0.1 ± 0.2 48 ± 1.2
0 100 100 100 100 100 100 100 100 100
15 98 ± 8.6 96 ± 12.6 81 ± 8.7 105 ± 6.4 106 ± 6 102 ± 1.2 101 ± 6.5 106 ± 7.6 41 ± 1




60 100 ± 7.8 115 ± 4.3 38 ± 4.2 100 ± 9.4 100 ± 10.5 95 ± 0.2 105 ± 10.5 104 ± 4.5 34 ± 2
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Table S-4. Human microsomal stability.*This experiment was performed only once.
Microsomal stability
% remaining parent compound
Microsomes Phase I/II
Time 
(min) 1 2 11 14 17 26 Diclofenac*
0 100 100 100 100 100 100 100
15 56.7 ± 5.3 4.5 ± 1.5 6.1 ± 1.3 96 ± 4.1 2.1 ± 0.4 41 ± 18.6 44
30 21.8 ± 4.9 0.9 ± 0.1 2.6 ± 1.7 89 ± 12.5 0.1 ± 0.1 23 ± 8.4 16
CYP450-
NADPH
60 5 ± 1.8 0.4 ± 0.2 1 ± 0.7 80 ± 9.2 0.1 ± 0.0 15 ± 10.3 3.8
0 100 100 100 100 100 100 100
15 98 ± 1.1 101 ± 0.0 4.9 ± 0.2 98 ± 6.5 93 ± 5.4 82 ± 10.7 21




60 109 ± 7.7 105 ± 0.1 2.2 ± 0.3 100 ± 2.6 95 ± 0.3 55 ± 10.6 11
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Microsomal stability
 % remaining parent compound
Microsomes Phase I/II
Time 
(min) 28 35 38 44 48 61 diclofenac
0 100 100 100 100 100 100 100
15 73 ± 3 33 ± 0.4 63 ± 5.5 12 ± 1.1 58 ± 2.3 3.9 ± 0.4 44
30 48 ± 3 11 ± 2.4 37 ± 6.7 4.2 ± 2.9 43 ± 4.1 0.3 ± 0.4 16
CYP450-
NADPH
60 23 ± 0.5 1.4 ± 0.8 14 ± 4.8 2.7 ± 2.2 23 ± 3.1 0.3 ± 0.1 3.8
0 100 100 100 100 100 100 100
15 120 ± 9.7 97 ± 0.4 114 ± 1.1 4.6 ± 0.9 104 ± 0.2 100 ± 5 21




136 ± 17.9 101 ± 2.8 112 ± 19.3 3.2 ± 0.5 102 ± 2 105 ± 1.3 11
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Production of recombinant TbrPDEB1 and hPDE4D2 catalytic domains
A gene segment coding for TbrPDEB1 catalytic domain residues 565–918 (Uniprot entry 
Q8WQX9) was PCR amplified and cloned into E. coli expression vector pET28a(+) using 
NdeI and EcoRI restriction sites. The resulting vector was named pET28a(+)-
TbrPDEB1_CD. Similarly, PCR amplification of the coding sequence for hPDE4D2 
catalytic domain residues 381–740 (Uniprot entry Q08499) was performed and the 
product was cloned into a pET15b(+) E. coli expression vector using NdeI and XhoI 
restriction sites. The resulting vector was named pET15b(+)-hPDE4D_CD. Vector 
encoded N-terminal 6xHis tag was kept in frame for both constructs to facilitate 
purification.  
For expression, TbrPDEB1_CD transformed E. coli BL21(DE3) cells were allowed to 
grow in 2xYT media at 37 °C until the optical density at 600 nm reached 0.6–0.8. The 
temperature was reduced by cooling and the cultures were induced with 1 mM isopropyl 
b-d-1-thiogalactopyranoside followed by overnight growth at 16 OC. Cells were collected 
by centrifugation, resuspended in lysis buffer (20 mM Tris-HCl pH 7.5, 200 mM NaCl, 
10 mM imidazole, 5% glycerol, 2 mM β-mercaptoethanol (BME), protease inhibitor 
cocktail tablet) and lysis was performed using a cell disruptor (20 kpsi / 1 pass). Cleared 
cell lysate was loaded onto a 5 mL HisTrap HP nickel affinity column (GE Healthcare 
Biosciences) and bound protein was eluted with a linear gradient of 0–1 M imidazole. 
Pooled fractions were desalted to remove imidazole and the N-terminal 6xHis tag was 
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removed by overnight incubation at 4 °C with human thrombin (Abcam or Sigma-
Aldrich). Any tagged fraction was removed by a second nickel affinity purification step 
and the protein was loaded onto a 5 ml HiTrap Q HP column (GE Healthcare Biosciences) 
prequilibrated with ion exchange buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 5% 
glycerol, 2 mM BME). Elution was performed with a linear gradient of 0–1 M NaCl and 
the pooled fractions were subjected to size exclusion chromatography step using a 
Superdex 200 increase 10/300 GL column (GE Healthcare Biosciences) prequilibrated in 
a buffer containing 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 5% glycerol, 2 mM BME. 
The eluted protein was stored in the same buffer from which NaCl was removed prior to 
crystallization trials.
Expression and purification of hPDE4D2 catalytic domain was performed in a similar 
way as for TbrPDEB1-CD with the following changes in buffers used: cell lysis and 
nickel affinity chromatography buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 5 mM 
BME, 20 mM imidazole), ion exchange chromatography buffer (50 mM Tris-HCl pH 8, 
50 mM NaCl, 5 mM DTT) and size exclusion chromatography buffer (50 mM Bis-tris 
pH 6.8, 100 mM NaCl, 5 mM DTT).
 Crystallisation, diffraction data collection and structure solution of inhibitor 
complexes:
Crystals of TbrPDEB1-CD and hPDE4D2-CD were obtained in 24 well XRL plates 
(Molecular Dimensions) by vapor diffusion hanging drop technique, typically with 500 
µL reservoir volume and 2 µL droplets with a protein to crystallization solution ratio of 
1:1. Crystals of 
TbrPDEB1-CD were obtained in a condition containing 20% PEG 3350, 400 mM sodium 
formate, 300 mM guanidine, 100 mM MES, pH 6.5 at 4 °C and that of hPDE4D2-CD in 
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24% PEG 3350, 30% ethylene glycol and 100 mM HEPES, pH 7.5 at 19 °C. For soaking 
experiments, 10-15 mM solutions of inhibitors NPD-226, NPD-356, NPD-1086 and 
NPD-1439 were prepared in respective crystal growth conditions and crystals were 
allowed to soak from overnight to 48 hours duration. In case of TbrPDEB1-CD, the 
soaked crystals were briefly dipped in soaking solutions supplemented with 15% glycerol 
for cryo protection, mounted on CryoLoop (Hampton Research) or LithoLoops 
(Molecular Dimensions) and vitrified in liquid nitrogen for data collection. Soaked 
hPDE4D2-CD crystals were harvested in a similar way, albeit without any cryo protection 
step.  X-ray diffraction data sets were collected at Diamond Light Source (DLS; Didcot, 
Oxfordshire, UK) beamline I03 and processed by xia227 or autoPROC,28 which 
incorporates XDS29 and AIMLESS,30 or were integrated using iMOSFLM31 and reduced 
using POINTLESS, SCALA and TRUNCATE, all of which are part of CCP4.32
Structure solution, refinement and analysis
Structure of inhibitor bound complexes were determined by molecular replacement using 
CCP4 suite program Phaser33 that utilised apo models of TbrPDEB1-CD (PDB id: 4I15) 
and hPDE4D2-CD (PDB id: 3SL3) as search templates or by direct Fourier synthesis 
method. Ligand descriptions were generated by ACEDRG available within the CCP4 
pacakage32. Manual model adjustment and ligand fitting were performed in COOT34 
followed by model refinement with REFMAC.35  Fully refined models were validated 
with MOLPROBITY.36 Data collection and refinement statistics are given in Table 2S 
and 3S. Figures were prepared with PyMOL37. Coordinates of the structures have been 
deposited to the RCSB Protein Data Bank with following accession codes: 6FDS 
(TbrPDEB1–compound 1); 6FDW (TbrPDEB1–compound 11); 6FDX (TbrPDEB1–
compound 12); 6FE3 (TbrPDEB1–compound 35); 6FDI (hPDE4D–compound 1); 6FE7 
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(hPDE4D- compound 11); 6FEB (hPDE4D– compound 12); 6FET (hPDE4D– compound 
12).
Table S-5. Data collection and refinement statistics for TbrPDEB1 catalytic domain 
crystals in complex with various inhibitors 
1 11 12 14  35
Data collection




2 2 2 2 2



























































99.5 (99.7) 99.5 (99.8) 97.1 (96.7) 98.1 (98) 97.0 (80.4)
Redundancy 2.8 (2.9) 3.4 (3.4) 3.4 (3.5) 3.3 (3.4) 3.3 (2.5)
Refinement
Resolution (Å) 2.20 1.96 2.31 2.47 1.62










Rwork / Rfree 0.193/0.240 0.190/0.237 0.169/0.232 0.206/0.254 0.165/0.190
No. atoms
    Protein 5260 5252 5260 5260 5268
    Ligand 80 74 76 74 44^
    Water 178 232 144 373 500
B-factors
    Protein 63.67 53.16 67.39 23.27 32.20
    Ligand 77 53.73 63.28 39.77 42.24
R.m.s. 
deviations
    Bond lengths 
(Å)
0.014 0.017 0.013 0.011 0.019
    Bond angles 
()




6FDS 6FDW 6FDX 6FV9 6FE3
PDB ligand 
code
D5T D62 D5Z E8H D68
Data were collected from one crystal in each case. *Values in parentheses are for highest-
resolution shell. ^Ligand present at only one protein molecule 
Table S-6. Data collection and refinement statistics for hPDE4D catalytic domain crystals 
in complex with various inhibitors 
1 11 12 14 35
Data collection
Space group P 21 21 21 P 21 21 21 C 2 2 21 P 21 21 21 P 21 21 21
Molecule/a.s.u
Cell dimensions  
4 4 2 4 4


















































100 (100) 100 (100) 99.1 (99.5) 100 (100) 100 (100)
Redundancy 6.8 (6.6) 6.7 (6.8) 6.6 (6.8) 6.4 (5.5) 6.7 (6.6)
Refinement
Resolution (Å) 1.90 2.0 1.92 1.78 1.88










Rwork / Rfree 0.174/0.200 0.170/0.200 0.160/0.196 0.177/0.214 0.171/0.199
No. atoms
    Protein 10573 10532 5246 10531 10523
    Ligand 160 148 114 148 176
    Water 831 670 302 941 625
B-factors
    Protein 31.33 40.18 39.26 30.88 39.90
    Ligand 35.08 48.18 45.58 36.88 45.02
R.m.s. deviations
    Bond lengths 
(Å)
0.014 0.018 0.014 0.019 0.018
    Bond angles 
()
1.599 1.894 1.625 1.900 1.881
PDB accession 
no.
6FDI 6FE7 6FEB 6FW3 6FET
PDB ligand code D5T D62 D5Z E8H D68
Data were collected from one crystal in each case. *Values in parentheses are for highest-
resolution shell. ^Ligand present at only one protein molecule 
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Figure S-1. Crystal structure of hPDE4D in complex with selected inhibitors: compound 14 
(panel A), compound 1 (panel B), compound 11 (panel C), compound 12 (panel D) and compound 
35 (panel E). Inhibitors are shown in orange sticks, metal center ions magnesium and zinc are 
shown in magenta and grey spheres respectively, residues Phe372 and Ile336, which forms the 
hydrophobic clamp, and Met357, which interacts with tail heterocyclics, are shown in yellow 
lines while conserved Gln369 is depicted by green sticks. Hydrogen bond interactions between 
Gln369 and phthalazinone substitutes are highlighted by black dashed lines. 
